Home Journals Articles Updates About
CN
image
收藏切换
EGFR exon 20 insertion mutation in non-small cell lung cancer: classification and clinical treatment research
收藏切换
PDF
Run LI1, Hong-jie GUO2, Xi CHEN2, *, Ling DING2, *
Acta Pharmaceutica Sinica | 2021, 56(5) : 1201 - 1210
Less
收藏切换
Acta Pharmaceutica Sinica | 2021, 56(5): 1201-1210
• Reviews •
EGFR exon 20 insertion mutation in non-small cell lung cancer: classification and clinical treatment research
Full
Run LI1, Hong-jie GUO2, Xi CHEN2, *, Ling DING2, *
Affiliations
  • 1. Zhejiang Chinese Medical University, Hangzhou 310053, China
  • 2. Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
Published: 2021-05-12 doi: 10.16438/j.0513-4870.2020-1852
Outline
收藏切换

In recent years, targeted therapy has become the standard treatment for advanced non-small cell lung cancer (NSCLC), but this treatment method has very limited effect on patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation. This insertion mutation is the third most common mutation in EGFR. It shrinks the drug binding pocket and gives tumors inherent resistance to available EGFR tyrosine kinase inhibitors (TKIs), resulting in the limited efficiency of the first and second generation of EGFR tyrosine. So far, no targeted therapy has been approved for NSCLC patients with EGFR exon 20 insertion mutations, and there are still no drugs that have met clinical needs. In this case, new treatment strategies using new EGFR TKIs or bispecific antibodies may establish new treatment standards for these patients in the future. In this review, we will summarize all relevant exon 20 insertions reported so far on the structure of EGFR and its influence on EGFR inhibitor sensitivity, as well as the treatment strategies of exon 20 insertions in NSCLC patients, hoping to be a clinical treatment for reference.

epidermal growth factor receptor  /  exon 20  /  insertion mutation  /  tyrosine kinase inhibitor  /  clinical treatment
Run LI, Hong-jie GUO, Xi CHEN, Ling DING. EGFR exon 20 insertion mutation in non-small cell lung cancer: classification and clinical treatment research[J]. Acta Pharmaceutica Sinica, 2021 , 56 (5) : 1201 -1210 . DOI: 10.16438/j.0513-4870.2020-1852
Appendix
Less
Year 2021 volume 56 Issue 5
PDF
133
48
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2020-1852
  • Receive Date：2020-12-08
  • Online Date：2025-12-18
  • Published：2021-05-12
Article Data
Affiliations
History
  • Received：2020-12-08
  • Revised：2021-01-14
Funding
Affiliations
    1. Zhejiang Chinese Medical University, Hangzhou 310053, China
    2. Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2020-1852
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House